Pharmaceutical-grade medical cannabis, cultivated in the UK.
Sunny Organics is building a controlled-environment cultivation operation designed around Good Manufacturing Practice, full traceability and the UK's regulatory framework, to supply consistent, high-quality starting material for medical use.
Quality patients and prescribers can rely on.
Patients deserve medicines that are consistent from one batch to the next. We are establishing a UK cultivation business focused on producing medical cannabis to pharmaceutical standards, with rigorous process control at every stage from propagation to post-harvest.
We intend to work alongside licensed manufacturers, pharmaceutical partners and researchers, operating transparently and in full cooperation with UK regulators.
“Grown with care, controlled with precision, and accountable at every step.”
Built for compliance from day one.
Our operating model is being designed to meet the expectations of UK and international regulators and the pharmaceutical partners we serve.
Pharmaceutical standards
Processes designed to align with EU-GMP and GACP principles, with validated, documented procedures.
Regulatory compliance
Working within the Misuse of Drugs Act framework, Home Office licensing and MHRA requirements.
Quality & traceability
Seed-to-sale batch records, controlled genetics and independent laboratory testing of every batch.
Responsible cultivation
Controlled indoor environments with a focus on energy efficiency, water stewardship and minimal waste.
Where we are today.
We are at an early stage and will share updates as each milestone is reached.
- Complete
Company formation
Business established and leadership team in place.
- In progress
Licensing & site planning
Preparing licence applications, facility design and quality systems.
- Planned
Facility build & validation
Construction, commissioning and validation of the cultivation facility.
- Planned
Partnership supply
Supply of compliant starting material to licensed partners.
Interested in working with us?
We welcome conversations with pharmaceutical manufacturers, researchers, investors and industry partners.